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Pediatric migraine remains still a challenge for the headache specialists as concerns both
diagnostic and therapeutic aspects. The less ability of children to describe the exact
features of their migraines and the lack of reliable biomarker for migraine contribute
to complicate the diagnostic process. Therefore, there’s need for new effective tools
for supporting diagnostic and therapeutic approach in children with migraine. Recently,
promising results have been obtained in adult headache by means of application of
neurostimulation techniques both for investigating pathophysiological mechanisms and
also for therapeutical applications. Non-invasive brain stimulation (NIBS) techniques
like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation
(tDCS) indeed proved to be generally safe and showing also some evidence of efficacy
particularly for the symptomatic treatment. On such basis, in the last years increasing
interest is rising in scientific pediatric community to evaluate the potential of such
approaches for treatment pediatric headaches, particularly in migraine, even if the
evidence provided is still very poor. Here we present a perspective for application of
TMS and tDCS technique in children migraine principally based on evidence coming by
studies in adults.
Keywords: transcranial magnetic stimulation, transcranial direct current stimulation, non-invasive brain
stimulation, pediatric migraine, therapeutics
INTRODUCTION
Pediatric migraine remains a challenge for headache specialists, as concerns both diagnostic and
therapeutic aspects. The low ability of children to describe the exact features of their migraines
and the lack of reliable biomarkers complicate the diagnostic process, while symptomatic and
prophylactic treatments are limited due to placebo effect and the parents’ fear of pharmacological
side effects (1–3). Therefore, there is a need for new effective tools for supplementing the existing
diagnostic and therapeutic approaches in children with migraine.
Recently, promising results have been obtained in adult headache by applying neurostimulation
techniques for investigation of pathophysiological mechanisms as well as for identification of
potential clinical biomarkers, and last, but not least, of possible better-tolerated therapeutic
alternatives (4). On such basis, over the last few years, the scientific pediatric community has
become increasingly interested in evaluating these methods with respect to the therapeutic
approach to pediatric headaches, particularly migraine.
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Non-invasive brain stimulation (NIBS) techniques are defined
as neurophysiological approaches for transcranial application
of electrical currents or magnetic fields that are able to
modulate brain activity, and are employed for investigating
pathophysiology and also as diagnostic and therapeutic tools
in many neuropsychiatric diseases (4). The first reported
application of neurostimulation dates back to the first century
AD, when Scribonius Largus relieved pain using the black
torpedo, a bioelectric fish, delivering an electrical pulse to the
painful area (5). Subsequently, from nineteenth century onward,
new electrical generators were utilized; since then, the application
of electric stimulation of the vagal nerve has been used, at first, for
treatment of refractory epilepsy, and later, also in different pain
states (4). Other NIBS techniques have also been experimented
with for treatment of pain and other neuropsychiatric diseases
in adults, but in the field of pediatric headache, only some
anecdotal reports are available. The majority of these reports are
principally aimed at exploration of safety issues associated with
the techniques (6–9).
Neuromodulation can modify the activity of several brain
networks by modulating neuronal excitability, and excitatory or
inhibitory effects, depending on different stimulation parameters
(polarity, duration, or frequency of stimuli) (4). The NIBS
techniques have the relevant advantage of inducing brain
changes by non-invasive stimulation, which does not require
intervention for application of permanent leads, is painless and
optimally tolerated, and can be employed in awake subjects at
rest or during execution of different tasks. These techniques
function through transcranial application of magnetic or electric
currents (transcranial magnetic [TMS] and electrical stimulation
[tES], respectively).
In TMS, weak but rapid electric currents are elicited in the
brain regions through fast variation of magnetic field (4), which
activates cortical neurons, triggering them to discharge; TMS can
be delivered in a single pulse, double pulse, or trains of repeated
pulses (repetitive TMS [rTMS]). The first modality has been
principally employed to study brain physiology and for diagnosis
of diseases of the motor system and pathways, but has also found
therapeutic application in symptomatic treatment of migraine
with aura attack (10).
Double-pulse TMS has found application in investigation
of cortical facilitation and inhibition owing to the ability of
paired stimulation to selectively modulate cortical inhibitory or
facilitatory circuits depending on the interval between the pulses
(11, 12). Further, rTMS can induce lasting effects determining
prolonged neuroexcitability-related changes that remain
beyond stimulation, suggesting the potential for therapeutic
use in neuropsychiatric diseases with abnormal (increased
or decreased) cortical excitability, especially for long-term
treatment (13). Generally, high-frequency stimulation increases
cortical excitability while low-frequency decreases it; however,
several modifications of stimulation parameters allow flexibility
in the brain responses obtained, depending further on different
diseases (4, 9).
Conversely, tES functions through application of direct or
alternating weak currents (0.5–2mA), delivered via electrodes
attached to the scalp. The initial, and yet most frequent,
approach is based on application of direct currents (transcranial
direct current stimulation [tDCS]); tDCS acts by modulating
neuronal excitability. Contrary to TMS, tDCS is not able to
induce direct neural activation but affects excitability through
polarization. Anodic currents induce depolarization, increasing
excitability and the probability of spontaneous firing, while an
opposite inhibitory effect is induced by cathodal stimulation
through neuronal hyperpolarization (13). Further, tDCS is
able to induce long-lasting neuroplastic effects that have
been found to be critically dependent on glutamate-NMDA
neuro-transmission and represents the physiological basis for
therapeutic application (4, 13).
Here we present a perspective about the potential of
NBS techniques in children migraine based on data about
safety, coming from studies on other disease in children,
and on evidence about efficacy by TMS and tES studies in
adult migraineurs.
SAFETY OF TMS AND tDCS IN THE
PEDIATRIC POPULATION
The safety of NIBS techniques has been mainly studied in the
adult population, and there are only a few reports on their
use in the pediatric population (6–9). These pediatric studies
investigated mainly single-pulse or paired-pulse TMS protocols
that are not of therapeutic interest. A recent report examined in
detail the issue of safety of TMS and tDCS in children through an
extensive review of the articles published till 2014; based on an
electronic search, 48 studies were found and evaluated, including
a population of more than 500 children, and adolescents aged
2.5–17.8 years (9). The NIBS methods were used in several
disorders (autism, epilepsy, depression, etc.). In nine studies,
patients underwent only a single stimulation session while in
the others, designed for therapeutic purposes, more stimulation
sessions were applied; the frequency and number of stimulation
sessions varied across reports, ranging from repeated daily to
weekly sessions. In these studies, TMS was the most commonly
applied NIBS technique, with different parameters of stimulation
on referred thresholds as control, globally reporting only 1.2%
important negative side effects (seizure and syncope). Minor side
effects were headache, scalp discomfort, fatigue, neck stiffness,
etc. Headache is a more frequent side effect (11.5%), although
it is temporary and usually does not need any therapy. Sixteen
studies were found to have used tDCS, accounting for more
than 190 subjects, and the methodology varied considerably for
range of intensity, session duration, and session number. Serious
side effects were not reported, while mild side effects (redness,
tingling, itching sensation, etc.) were reported in cumulative
analysis, with the frequency ranging from 1.5 to 11.5%; they
were transitory and no medical treatments were needed. The
authors’ conclusion was that TMS and tDCS are safe (1% serious
adverse effect); however, considering that the majority of the data
obtained using these methods originate from adult studies, it
is necessary to follow some precautions, such as not including
subjects with alcohol consumption, epileptogenic medication
intake, recent cranial trauma, or history of seizures. Further, the
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authors suggested searching for possible history of syncope in
order to minimize the risks. The fact that headache was the more
common mild side effect suggests the contraction of the muscles
near the stimulation site as a possible cause. Headache, always
mild and brief, was also reported in the sham groups (i.e., placebo
stimulation), suggesting non-specific effects.
The tDCS appears to present fewer side effects, especially
those related to the site of stimulation, and local symptoms
are principally observed in the adult population, whereas no
skin lesion is reported in children. In the adult population,
repeated tDCS sessions did not appear to increase side effects
(14); however, the lack of studies with prolonged repetition over
time does not allow clear conclusions to be drawn regarding
long-term safety of tDCS in these populations, even if studies on
animal models suggest safety of long-term use (15).
Our actual conclusion on the safety of using TMS and tDCS
in the pediatric population are limited by the low sample size
(∼500 subjects), variability in the stimulation parameters that
does not allow correlation between specific parameters and side
effects, few long-term studies, the fact that many studies are
performed on other outcomes and not specifically to evaluate
the safety via appropriate questionnaires or follow-up, the lack
of correlation with structural, neurophysiological, and general
data (MRI, different neurophysiological alterations, or blood
test results).
DIAGNOSTIC AND THERAPEUTIC USE OF
TMS AND tDCS IN THE PEDIATRIC
MIGRAINOUS POPULATION
Several cortical and subcortical areas are involved in the
pathogenesis of pain and migraine; a central role is played by
the trigeminocervical complex, which has sensitive afferents and
connections with the autonomic nervous system, as well as
other subcortical and cortical centers. The trigemino-vascular
system and trigemino-autonomic reflexes are believed to be
involved in the main mechanism of migraine pain through
multiple vasoactive peptides (calcitonin gene-related peptide,
substance P, vasoactive intestinal peptide, pituitary adenylate
cyclase-activating peptide, etc.) (16). Cortical and subcortical
areas (the occipital and associative cortices, hypothalamus,
periaqueductal gray, and locus coeruleus) are believed to
activate, inhibit, or modulate the trigeminocervical complex (17).
Peripheral and central sensitization mechanisms are invoked
as causes of signs and symptoms of migraine attack and
chronicization (18). On these bases, it is reasonable that each of
the aforementioned nodes could represent a target of putative
non-pharmacological strategies.
Visual aura has been extensively investigated as a marker of
cortical dysfunction. The TMS has been used to analyze cortical
excitability through the phosphene thresholds in migraineurs
and controls (19–21). A single pulse applied to the visual cortex
can induce an artificial percept or “phosphene,” which may
be enhanced by adding a conditioning stimulus. The evoked
phosphenes increase depending on the stimulation intensity,
allowing establishment of the “phosphene threshold” of a subject.
The phosphene threshold may also be modulated by TMS stimuli
applied to the associated cortical area. Phosphene-induction
using TMS allows assessment of the occipital cortex excitability in
subjects with and without migraine. In the adult population, data
suggest the existence of primary visual cortex hyperexcitability,
especially in migraine with aura (21). These studies are limited
by variability of stimulation parameters in absence of uniformly
adopted protocol for measuring phosphenes; however, response
to TMS seems to be a very promising biomarker for migraine.
Recently, anodal tDCS application to the temporal pole has been
shown to enhance interictal excitability of the visual cortex in
migraineurs, restoring normal habituations, underlining the role
of the temporal pole in visual processing (22).
Evidently, in the pediatric population, the data are few
and sparse, and show lower phosphene thresholds in interictal
migraineurs vs. controls, with changing excitability levels 1–2
days before migraine attacks, reflecting the relation of fluctuating
excitability to the migraine cycle (23). To date, to our knowledge,
only one pivotal study (24) in adolescents affected by migraine
has explored the therapeutic use of rTMS as a preventive
treatment, showing reduction in the number of headache days,
use of abortive drugs, and MIgraine Disability Assessment score,
and safe use and few side effects. However, the study has
several limitations, such as an open-label design and small
sample population.
The matter, however, is worth investigating further because
NIBS showed promise in the treatment of pain and migraine
in adults. High-frequency magnetic stimulation of the motor
cortex indeed showed level A evidence of effectiveness against
neuropathic pain (13). A large randomized study on a population
migraineurs with visual aura using single-pulse stimulation
for acute attacks showed significantly greater improvement
following real stimulation, compared with sham stimulation, at
2 and 24 h with regard to the following outcome measures: pain
relief, nausea, and phono- and photo-phobia, in the absence of
side effects (10). The limitations of the study were mainly the
sample population exhibiting only migraine with visual aura;
moderate gain on sham effect (17%), lower than that reported
using traditional therapeutic drugs such as triptans (25); and
the difficulty in achieving a true blind effect with this method.
The results from the ESPOUSE Study (26) (observational post-
marketing study) support the possible therapeutic effect of TMS
as a preventive agent against adult migraine, with low-to-mild
side effects and no serious adverse effects. Recently, the US Food
and Drug Administration has authorized the use of single-pulse
TMS for abortive therapeutic purposes (27).
In chronic migraine, the available results on rTMS
prophylactic therapy are contradictory, with the few published
studies having small sample populations, lack of consensus
regarding brain targets, variation in stimulation parameters, and
issues related to the utilized masks, causing difficulties in their
comparison and establishment of clear conclusions regarding the
effectiveness of TMS against chronic migraine (28–30). However,
the generally reported lack of side effects and the potential of
this method make its use promising in the pediatric population,
where the parents’ fear of side effects is an important limitation
on the use of pharmacological drugs (31).
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tDCS IN PAIN AND MIGRAINE
To our knowledge, studies using tDCS in the treatment of
pediatric migraine and pain have not yet been published.
However, observing the increasing number of instances of
tDCS use in adult pain and considering the data from its
use in other pediatric disorders, we can hypothesize the
effective application of this technique in pediatric pain.
Evidence regarding the effect of tDCS on adult patients
with migraine is still inconclusive; however, two studies
applying cathodal currents over the primary visual cortex
showed a significant amelioration of the symptoms compared
with the baseline, pretreatment condition with respect to
duration, intensity, and severity of attacks, even though
only the intensity changed significantly compared with
placebo sham stimulation (32, 33). No severe adverse effects
were reported, with good tolerability. In a meta-analysis,
Luedtke et al. (34) concluded that clinical data does not
support the use of tDCS in the treatment of pain and
migraine. However, the authors advise designing studies
with larger sample populations using shared protocols
on stimulation parameters and stimulation sites to better
evaluate the effectiveness of this method, which is promising due
to its low cost, easy applicability, non-invasiveness, and lack of
serious adverse effects. These aspects are even more relevant in
the context of the pediatric population, where tolerability, and
non-invasiveness are critical characteristics for its consideration
for therapeutic treatment.
POTENTIAL STRATEGIES FOR TMS AND
tDCS APPLICATION IN PEDIATRIC PAIN
AND MIGRAINE, AND CONCLUSIONS
TheCochrane reviews do not provide clear conclusions regarding
the effectiveness of TMS and tDCS against adult chronic pain,
although small benefits appear to have been observed. However,
the authors point out many biases and important heterogeneities
of these studies (30).
At the moment, it is not possible to establish useful
guidelines on the use of TMS and tDCS in the treatment of
pediatric migraine and, in general, for pediatric pain treatment.
However, adult studies as well as preliminary pediatric reports
show that the application of these techniques is safe, with
few side effects, potentially low costs, and easy applicability.
Furthermore, in adults, for some serious painful disorders, such
as chronic regional pain syndrome, level A evidence has been
obtained regarding the pain-relieving effects of these techniques.
Preliminary reports, principally in adults but also in the pediatric
population, suggest that migraine may represent an effective
therapeutic target. Moreover, NBS of cortical areas as DLPFC,
that has been explored in migraine, was found to be effective
for treatment of other conditions, that are comorbid with
disease, sharing also a stimulation target employed for migraine
treatment, like DLPFC. Among these disorders, in addition to the
role played by the psychiatric diseases, of particular importance is
obesity which also favors the chronification of migraine (35, 36).
Due to the large prevalence of the disease and the disability
associated with it, and also considering the parents’ relevant fears
and concerns regarding pharmacological therapies, especially
for continuing preventive treatment, pediatric migraine appears
to be an optimal candidate for future studies on therapeutic
NIBS. Therefore, this topic is worth exploring further through
rigorous, opportunely suited randomized controlled trials with
uniform diagnostic protocols, and stimulation parameters to
reveal the real therapeutic potential of NIBS techniques against
pediatric migraine.
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